ChemoCentryx

^{Priced, Nasdaq: CCXI.XX}

Developing novel drugs for Crohn's disease and rheumatoid arthritis with Glaxo.

Industry: Health Care

First Day Return: +10.0%

CCXI.XX

Developing novel drugs for Crohn's disease and rheumatoid arthritis with Glaxo.

IPO News for ChemoCentryx

TPG-backed biotech Virobay files for a $50 million IPO 09/10/14
ChemoCentryx quiet period ends March 19 03/14/12
Caesars stands out in a busy pricing week with strong returns 02/10/12

IPO Data
IPO Date	02/08/2012
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$45
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Website www.chemocentryx.com
Headquarters	Mountain View, CA, United States
Founded	1997
Employees at IPO	64

IPO News for ChemoCentryx

TPG-backed biotech Virobay files for a $50 million IPO 09/10/14
ChemoCentryx quiet period ends March 19 03/14/12
Caesars stands out in a busy pricing week with strong returns 02/10/12

ChemoCentryx (CCXI.XX) Performance